Inc. (TSE: CRDL-OTCQX: CRTPF) President and CEO David Elsley joined Steve Darling from Proactive with news the company has been given the go-ahead for an investigational new drug application to commence a Phase II/III, double-blind, a placebo-controlled clinical trial investigating the efficacy and safety of CardiolRx.
Elsley talks about how and where this study is going to be conducted and he also talked about timing for CardiolRX and how this now speeds up the development.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Cardiol Therapeutics named herein, including the promotion by the Company of Cardiol Therapeutics in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
